Morgan Stanley Upgrades ResMed (RMD) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Morgan Stanley Upgrades ResMed (RMD) to Overweight
July 31, 2015 8:02 AM EDT
Needham & Company analyst Mike Matson reiterated a Buy rating and raised his price target on ResMed (NYSE: RMD) to $66.00 (from $65.00) following solid Q4 results driven by flow generator product cycle.
Matson commented, "RMD's revenue and EPS beat consensus as its revenue... More
July 31, 2015 7:32 AM EDT
Deutsche Bank downgraded ResMed (NYSE: RMD) from Hold to Sell with a price target of $53.00 (from $61.00). The change follows Q4 results. Analyst David Low noted strong sales offset by GM weakness.
"After the incredible success of ResMeds AirSense range we are wary FY16... More
July 30, 2015 4:52 PM EDT
ResMed (NYSE: RMD) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $453.1 million versus the consensus estimate of $436.73 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
...
More
